Company Overview

Johnson & Johnson, together with its subsidiaries, researches and develops, manufactures, and sells various products in the healthcare field worldwide. The company's Consumer Health segment offers baby care products under the JOHNSON'S and AVEENO Baby brands; oral care products under the LISTERINE brand; skin health/beauty products under the AVEENO, CLEAN & CLEAR, DR. CI:LABO, NEUTROGENA, and OGX brands; TYLENOL acetaminophen products; SUDAFED cold, flu, and allergy products; BENADRYL and ZYRTEC allergy products; MOTRIN IB ibuprofen products; NICORETTE smoking cessation products; and PEPCID acid reflux products. It also offers STAYFREE and CAREFREE sanitary pads; o.b. tampons; adhesive bandages under the BAND-AID brand; and first aid products under the NEOSPORIN brand. It serves general public, retail outlets, and distributors. The company's Pharmaceutical segment offers products for rheumatoid arthritis, psoriatic arthritis, inflammatory bowel disease, and psoriasis; HIV/AIDS and COVID-19 infectious diseases; mood disorders, neurodegenerative disorders, and schizophrenia; prostate cancer, hematologic malignancies, lung cancer, and bladder cancer; thrombosis, diabetes and macular degeneration; and pulmonary arterial hypertension. This segment serves retailers, wholesalers, distributors, hospitals, and healthcare professionals directly for prescription use. Its MedTech segment provides electrophysiology products to treat cardiovascular diseases; neurovascular care products to treat hemorrhagic and ischemic stroke; orthopaedics products in support of hips, knees, trauma, spine, sports, and other; advanced and general surgery solutions that focus on breast aesthetics, ear, nose, and throat procedures; and disposable contact lenses and ophthalmic products related to cataract and laser refractive surgery under the ACUVUE brand. This segment serves wholesalers, hospitals, and retailers. The company was founded in 1886 and is based in New Brunswick, New Jersey.

  • Name

    Johnson & Johnson

  • CEO

    Mr. Joaquin Duato

  • Website

    www.jnj.com

  • Sector

    Pharmaceuticals

  • Year Founded

    1886

Profile

  • Market Cap

    $401.99B

  • EV

    $418B

  • Shares Out

    2,407.24M

  • Revenue

    $86.58B

  • Employees

    131,900

Margins

  • Gross

    69.43%

  • EBITDA

    35.85%

  • Operating

    27.9%

  • Pre-Tax

    22.53%

  • Net

    43.91%

  • FCF

    22.91%

Returns (5Yr Avg)

  • ROA

    11.91%

  • ROTA

    97.91%

  • ROE

    30.03%

  • ROCE

    17.33%

  • ROIC

    15.91%

Valuation (TTM)

  • P/E

  • P/B

  • EV/Sales

  • EV/EBITDA

  • P/FCF

  • EV/Gross Profit

Valuation (NTM)

  • Price Target

    $171.32

  • P/E

  • PEG

  • EV/Sales

  • EV/EBITDA

  • P/FCF

Financial Health

  • Cash

    $25.48B

  • Net Debt

    $16.02B

  • Debt/Equity

    0.58

  • EBIT/Interest

    31.45

Growth (CAGR)

  • Rev 3Yr

    -0.99%

  • Rev 5Yr

    1.26%

  • Rev 10Yr

    1.67%

  • Dil EPS 3Yr

    32.44%

  • Dil EPS 5Yr

    20.73%

  • Dil EPS 10Yr

    11.07%

  • Rev Fwd 2Yr

    3.43%

  • EBITDA Fwd 2Yr

    4.38%

  • EPS Fwd 2Yr

    3.89%

  • EPS LT Growth Est

    3.95%

Dividends

  • Yield

  • Payout

    71.53%

  • DPS

    $4.81

  • DPS Growth 3Yr

    5.55%

  • DPS Growth 5Yr

    5.67%

  • DPS Growth 10Yr

    6.02%

  • DPS Growth Fwd 2Yr

    4.52%

NYSE:JNJ